材料与方法：对32例临床诊断为支气管扩张的患者分别行胸片、CT、HRCT检查。
Materials and Methods:Chest film, conventional CT scanning, HRCT scanning were carried out in 32 patients with clinically-proved bronchiectasis.
大多数患者都是靠使用名为支气管扩张剂的吸入性药物、用氧和肺康复疗法来维持的。
Most patients are managed with the use of inhaled medications called bronchodilators, oxygen and pulmonary rehabilitation.
两组患者之间，支气管扩张剂使用前的FEV1平均值从3.14升减少到2.84升，但是预测值仍然恰好在气道功能的相同水平（89%预测值）。
Among both groups, the mean prebronchodilator FEV1 decreased from 3.14 l to 2.84 l, but the predicted value remained at exactly the same level of airway function (89% of predicted).
目的分析支气管扩张症伴咯血患者的供血动脉解剖分型及DSA表现。
Objective to analyze the anatomical features and DSA manifestations of supplying arteries in bronchiectasis with hemoptysis patients.
国外研究显示，新的药物包括新的支气管扩张剂和抗炎新药，将更好地治疗哮喘，减少不良反应，增加患者依从性。
Since the advances of clinical studies, some new anti-inflammatory drugs and bronchodilators with less adverse reaction, better effect and compliance are in development stage.
材料与方法：对长期慢性咳嗽、咳痰、咯血，疑诊为支气管扩张的15 0例患者，用离子型或非离子型造影剂行支气管造影检查。
Materials and methods: 150 patients with chronic cough, sputum and hemoptysis in whom bronchiectasis was suspected underwent bronchography using nonionic or ionic agent respectively.
结论：COPD患者行纤维支气管镜检查前不推荐吸入短效支气管扩张剂沙丁胺醇。
Conclusion: Premedication with an inhaled salbutamol cannot be recommended in patients with COPD undergoing bronchoscopy.
在研究期间，被指定接受布地奈德的吸烟患者使用支气管扩张器后FEV1值平均下降192.4ml，而非吸烟者平均下降134.3 ml。
Among patients assigned to take budesonide, smokers experienced a mean decline of 192.4 ml in post-bronchodilator FEV1 over the study period while non-smokers experienced a mean decline of 134.3 ml.
在研究期间，被指定接受布地奈德的吸烟患者使用支气管扩张器后FEV1值平均下降192.4ml，而非吸烟者平均下降134.3 ml。
Among patients assigned to take budesonide, smokers experienced a mean decline of 192.4 ml in post-bronchodilator FEV1 over the study period while non-smokers experienced a mean decline of 134.3 ml.
应用推荐